OCA
Octagon Capital Advisors Portfolio holdings
AUM
$456M
This Quarter Return
+21.17%
1 Year Return
+48.55%
3 Year Return
+560.4%
5 Year Return
–
10 Year Return
–
AUM
$717M
AUM Growth
+$717M
(+3.4%)
Cap. Flow
-$82.5M
Cap. Flow
% of AUM
-11.51%
Top 10 Holdings %
Top 10 Hldgs %
74.8%
Holding
47
New
11
Increased
6
Reduced
8
Closed
6
Top Buys
| 1 |
Disc Medicine
IRON
|
$18.4M |
| 2 |
Vir Biotechnology
VIR
|
$15.9M |
| 3 |
OKUR
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
|
$12.8M |
| 4 |
89bio
ETNB
|
$12.6M |
| 5 |
Insmed
INSM
|
$7.74M |
Top Sells
| 1 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
$59.1M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$57.5M |
| 3 |
Vera Therapeutics
VERA
|
$11.6M |
| 4 |
4D Molecular Therapeutics
FDMT
|
$8.59M |
| 5 |
Viridian Therapeutics
VRDN
|
$6.23M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Apellis Pharmaceuticals
APLS
$3.48B
| $239M | 33.19% | 2,618,300 -631,700 | -19% | -$57.5M |
|
|
VRNA
2
Verona Pharma
VRNA
$9.16B
| $52.2M | 7.26% | 2,468,000 | – | – |
|
|
CBAY
3
DELISTED
Cymabay Therapeutics
CBAY
| $50.1M | 6.96% | 4,570,918 | – | – |
|
4
Arcus Biosciences
RCUS
$1.13B
| $40M | 5.56% | 1,968,000 -204,000 | -9% | -$4.14M |
|
5
Roivant Sciences
ROIV
$8.15B
| $39.4M | 5.48% | 3,904,000 | – | – |
|
|
MRTX
6
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $27.1M | 3.77% | 750,000 | – | – |
|
7
Celldex Therapeutics
CLDX
$1.47B
| $25.8M | 3.59% | 759,898 | – | – |
|
|
8
Viridian Therapeutics
VRDN
$1.5B
| $22M | 3.06% | 923,000 -262,000 | -22% | -$6.23M |
|
9
BridgeBio Pharma
BBIO
$9.89B
| $21M | 2.92% | 1,219,200 -118,960 | -9% | -$2.05M |
|
|
10
89bio
ETNB
$1.34B
| $20.2M | 2.81% | 1,066,784 +666,784 | +167% | +$12.6M |
|
|
11
Disc Medicine
IRON
$2.07B
| $18.4M | 2.56% | +415,000 | New | +$18.4M |
|
|
12
Vir Biotechnology
VIR
$686M
| $15.9M | 2.22% | +650,100 | New | +$15.9M |
|
|
OKUR
13
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$37.2M
| $15.5M | 2.16% | 2,368,587 +1,948,587 | +464% | +$12.8M |
|
14
Tandem Diabetes Care
TNDM
$845M
| $11.7M | 1.62% | 474,929 | – | – |
|
|
JBIO
15
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $10.7M | 1.48% | 621,712 | – | – |
|
16
iTeos Therapeutics
ITOS
| $7.89M | 1.1% | 596,000 | – | – |
|
17
Dyne Therapeutics
DYN
$1.92B
| $7.8M | 1.08% | 692,945 | – | – |
|
|
18
Insmed
INSM
$28.8B
| $7.74M | 1.08% | +367,000 | New | +$7.74M |
|
|
ALPN
19
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $7.71M | 1.07% | 750,000 -452,000 | -38% | -$4.65M |
|
20
Travere Therapeutics
TVTX
$1.56B
| $7.6M | 1.06% | 495,000 | – | – |
|
21
Geron
GERN
$893M
| $7.31M | 1.02% | 2,278,000 | – | – |
|
22
Xilio Therapeutics
XLO
$36.3M
| $6.35M | 0.88% | 2,425,000 | – | – |
|
23
AN2 Therapeutics
ANTX
$30.1M
| $6.13M | 0.85% | +720,900 | New | +$6.13M |
|
24
Jasper Therapeutics
JSPR
$45.5M
| $6.12M | 0.85% | 4,468,114 -1,914,386 | -30% | -$2.62M |
|
25
Viking Therapeutics
VKTX
$3.04B
| $6.08M | 0.85% | 375,000 | – | – |
|